Vaccines manufacturer Serum Institute of India (SII) has started exports of ‘R21/Matrix-M’ malaria vaccine to Africa.
About R21/Matrix-M Vaccine:
- Developed by the University of Oxford and the Serum Institute of India (SII), the R21/Matrix-M vaccine leverages Novavax’s adjuvant technology to enhance the immune response.
- It targets P. falciparum, the most lethal malaria parasite predominantly found on the African continent.
- It has been recognized as the second malaria vaccine endorsed by the World Health Organization (WHO) in 2023, following the RTS,S/AS01 vaccine.
- R21/Matrix-M is the first malaria vaccine to achieve the WHO’s efficacy target of 75%.
- Approval for its use has been granted in Burkina Faso, Ghana, and Nigeria.
- The vaccine’s development received support from multiple organizations, including the European and Developing Countries Clinical Trials Partnership (EDCTP), the Wellcome Trust, and the European Investment Bank (EIB).
Ref: Source
| UPSC IAS Preparation Resources | |
| Current Affairs Analysis | Topperspedia |
| GS Shots | Simply Explained |
| Daily Flash Cards | Daily Quiz |